Emerging data suggest Retatrutide , a dual stimulator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may offer a promising step forward for body loss . Preliminary weight lose peptide patient investigations have shown substantial reductions in abdominal fat , conceivably surpassing current obesity medications .